Company / Capital Expenditures
GYRE THERAPEUTICS, INC. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.2M
FY2025
5-year range
$839.0K / $5.0M
FY2021-FY2025
Trend
-48.6%
vs FY2024
Sector context
#108 of 194
Health Care
What the data says
At $1M, GYRE THERAPEUTICS, INC.'s capital expenditures ranks #108 of 194 in the Health Care sector. Declined from $5M to $1M over the past 2 years.
Based on SEC 10-K filings.
$1M in FY2025 with a 3-year CAGR of -38.0%.
Declined from $5M to $1M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -38.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#108 of 194 in Health CareTop 56% of 194This company $1.2M Sector average $117.5M
▼
-99.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -38.0%, indicating a declining trend.
- In FY2025, capital expenditures decreased 48.6% year-over-year.
- Ranks #108 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2M | -48.6% |
| FY2024 | $2.3M | -53.6% |
| FY2023 | $5.0M | +0.0% |
| FY2022 | $5.0M | +494.2% |
| FY2021 | $839.0K | - |
| FY2020 | - | - |
| FY2019 | $64.0K | +178.3% |
| FY2018 | $23.0K | +0.0% |
| FY2017 | $23.0K | -95.1% |
| FY2016 | $468.0K | +72.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026